About Heron Therapeutics, Inc. - Common Stock (HRTX)
Heron Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative product candidates to address unmet medical needs in the treatment of various pain conditions and supportive care for patients undergoing chemotherapy. The company's expertise lies in harnessing proprietary formulations and delivery technologies to improve the efficacy and safety of existing therapies, thereby enhancing the overall patient experience. Heron Therapeutics is dedicated to advancing its pipeline of novel therapeutics aimed at providing effective solutions for managing acute pain and chemotherapy-induced nausea and vomiting, striving to improve the quality of life for patients. Read More
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Heron Therapeutics' Q4 2023 results: Beat EPS consensus at $(0.07), $34.23 million sales, up 14% Y/Y. Strong momentum in acute and oncology care franchises. Fiscal year 2024 guidance: $138 million-$158 million revenue, with positive adjusted EBITDA.
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24 insurance revenue guidance.
Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes. BlackBerry shares tumbled 17.2% to $2.9387 on Wednesday.
